产品
编 号：F381853
分子式：C7H6O3
分子量：138.12
分子式：C7H6O3
分子量：138.12
产品类型
规格
价格
是否有货
10g
200
In-stock
25g
320
In-stock
结构图
CAS No: 533-31-3
产品详情
生物活性：
Sesamol is a constituent of sesame oil. Sesamol shows a free radical scavenging activity. Sesamol shows an IC50=5.95±0.56 μg/mL in the DPPH assay. Anti-oxidant activities. Anticancer activities.
体内研究：
Sesamol treatment for 35 days does not significantly impact body weight, although the tumor volume is dramatically inhibited (40.56% size inhibitory rate with Sesamol at 200?mg/kg compared to the control group). However, a lower dose (100?mg/kg Sesamol) only has significant anti-tumor growth effect up to 27 days after the first treatment. The Bcl-2/Bax ratio in tumor tissues is also decreased. Moreover, in the Sesamol treatment group, levels of the cell proliferation marker Ki76 are down-regulated, and levels of the cell apoptosis marker cleaved-caspase 3 are increased when compared to control. The expression of LC3 protein is remarkably decreased by Sesamol in a dose-dependent manner.
体外研究：
Sesamol has also been shown to be a classical inhibitor of lipid peroxidation. Sesamol (0-1 mM) efficiently induces the apoptosis of human liver hepatocellular carcinoma (HepG2) cells. Sesamol suppresses cell proliferation and induces intrinsic and extrinsic apoptosis in HepG2 cells. Sesamol treatment elicites mitochondrial dysfunction by inducing a loss of mitochondrial membrane potential. Sesamol inhibits mitophagy and autophagy through impeding the PI3K Class III/Belin-1 pathway. Sesamol decreases the expression of anti-apoptotic protein Bcl-2, but shows no effect on the expression of apoptotic signal Bax. Sesamol improves the protein expression of Fas/FasL, and activates tBid and caspase-8 which are all involved in the extrinsic apoptosis pathway.
Sesamol is a constituent of sesame oil. Sesamol shows a free radical scavenging activity. Sesamol shows an IC50=5.95±0.56 μg/mL in the DPPH assay. Anti-oxidant activities. Anticancer activities.
体内研究：
Sesamol treatment for 35 days does not significantly impact body weight, although the tumor volume is dramatically inhibited (40.56% size inhibitory rate with Sesamol at 200?mg/kg compared to the control group). However, a lower dose (100?mg/kg Sesamol) only has significant anti-tumor growth effect up to 27 days after the first treatment. The Bcl-2/Bax ratio in tumor tissues is also decreased. Moreover, in the Sesamol treatment group, levels of the cell proliferation marker Ki76 are down-regulated, and levels of the cell apoptosis marker cleaved-caspase 3 are increased when compared to control. The expression of LC3 protein is remarkably decreased by Sesamol in a dose-dependent manner.
体外研究：
Sesamol has also been shown to be a classical inhibitor of lipid peroxidation. Sesamol (0-1 mM) efficiently induces the apoptosis of human liver hepatocellular carcinoma (HepG2) cells. Sesamol suppresses cell proliferation and induces intrinsic and extrinsic apoptosis in HepG2 cells. Sesamol treatment elicites mitochondrial dysfunction by inducing a loss of mitochondrial membrane potential. Sesamol inhibits mitophagy and autophagy through impeding the PI3K Class III/Belin-1 pathway. Sesamol decreases the expression of anti-apoptotic protein Bcl-2, but shows no effect on the expression of apoptotic signal Bax. Sesamol improves the protein expression of Fas/FasL, and activates tBid and caspase-8 which are all involved in the extrinsic apoptosis pathway.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备